SAR445761 - belumosudil, belumosudil
DFI17893
Phase 2 small_molecule active
Quick answer
SAR445761 - belumosudil, belumosudil for Chronic graft versus host disease. is a Phase 2 program (small_molecule) at Sanofi Pharma Bristol-Myers Squibb with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Sanofi Pharma Bristol-Myers Squibb
- Indication
- Chronic graft versus host disease.
- Phase
- Phase 2
- Modality
- small_molecule
- Status
- active